Page last updated: 2024-12-07

adenylosuccinate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

aspartyl adenylate: RN given refers to (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID447145
SCHEMBL ID198136
MeSH IDM0059043

Synonyms (39)

Synonym
l-aspartic acid, n-(9-(5-o-phosphono-beta-d-ribofuranosyl)-9h-purin-6-yl)-
unii-x1b4zj0iiv
x1b4zj0iiv ,
aspartyl adenylate
2-[9-(3,4-dihydroxy-5-phosphonooxymethyl-tetrahydro-furan-2-yl)-9h-purin-6-ylamino]-succinic acid
2SA ,
n6-(1,2-dicarboxyethyl)-amp
adenylosuccinate
C03794
n6-(1,2-dicarboxyethyl)amp
adenylosuccinic acid
19046-78-7
adenylosuccinic acid, ~96% (hplc)
DB04418
succinyl amp
(2s)-2-[[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]purin-6-yl]amino]butanedioic acid
n(6)-(1,2-dicarboxyethyl)amp
SCHEMBL198136
succinyladenosine monophosphoric acid
(2s)-2-[[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(phosphonooxymethyl)tetrahydrofuran-2-yl]purin-6-yl]amino]butanedioic acid
d-ribofuranosyl)-9h-purin-6-yl]
6-succino-5'-adenylate
succinyladenosine monophosphorate
succinyladenosine 5'-monophosphate
6-succino-5'-adenylic acid
d-ribofuranosyl-9h-purin-6-yl) mono(dihydrogen phosphate) (ester)
adenyl-succinic acid
AKOS030573831
(2s)-2-[(9-{(2r,3r,4s,5r)-3,4-dihydroxy-5-[(phosphonooxy)methyl]tetrahydrofuran-2-yl}-9h-purin-6-yl)amino]butanedioic acid (non-preferred name)
(s)-2-(9-((2r,3r,4s,5r)-3,4-dihydroxy-5-(phosphonooxymethyl)tetrahydrofuran-2-yl)-9h-purin-6-ylamino)succinic acid
Q27095207
l-aspartic acid, n-(9-(5-o-phosphono-.beta.-d-ribofuranosyl)-9h-purin-6-yl)-
n-(9-(5-o-phosphono-.beta.-d-ribofuranosyl)-9h-purin-6-yl)-l-aspartic acid
(s)-2-((9-((2r,3r,4s,5r)-3,4-dihydroxy-5-((phosphonooxy)methyl)tetrahydrofuran-2-yl)-9h-purin-6-yl)amino)succinic acid
HY-127137
CS-0093525
(s)-2-((9-((2r,3r,4s,5r)-3,4-dihydroxy-5-((phosphonooxy)methyl)tetrahydrofuran-2-yl)-9h-purin-6-yl)amino)succinicacid
l-aspartic acid, n-[9-(5-o-phosphono-beta-d-ribofuranosyl)-9h-purin-6-yl]-
DTXSID80864869
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (11)

PathwayProteinsCompounds
Purine Nucleotides De Novo Biosynthesis2945
Purine Nucleotides De Novo Biosynthesis 22945
Alanine,Aspartic acid and Asparagine metabolism ( Alanine,Aspartic acid and Asparagine metabolism )2237
Adenylo-succinic acid = AMP + Fumaric acid ( Purine nucleotides and Nucleosides metabolism )13
Purine nucleotides and Nucleosides metabolism ( Purine nucleotides and Nucleosides metabolism )10577
purine nucleotide metabolism (phosphotransfer and nucleotide modification)023
purine nucleotides de novo biosynthesis I039
superpathway of histidine, purine, and pyrimidine biosynthesis064
purine nucleotides de novo biosynthesis II033
salvage pathways of purine nucleosides I027
Biochemical pathways: part I0466

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (40.38)18.7374
1990's11 (21.15)18.2507
2000's13 (25.00)29.6817
2010's6 (11.54)24.3611
2020's1 (1.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.92%)5.53%
Reviews1 (1.92%)6.00%
Case Studies1 (1.92%)4.05%
Observational0 (0.00%)0.25%
Other49 (94.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]